See more : Sompo Holdings, Inc. (NHOLF) Income Statement Analysis – Financial Results
Complete financial analysis of Rallybio Corporation (RLYB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Rallybio Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
- AgriMinco Corp. (ETPHF) Income Statement Analysis – Financial Results
- Aegon Funding Company LLC (AEFC) Income Statement Analysis – Financial Results
- Informa plc (INF.L) Income Statement Analysis – Financial Results
- Groupe Parot SA (ALPAR.PA) Income Statement Analysis – Financial Results
- Hyve Group Plc (HYVE.L) Income Statement Analysis – Financial Results
Rallybio Corporation (RLYB)
About Rallybio Corporation
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; and RLYB116, a subcutaneously administered inhibitor of C5 for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 150.00K | 167.00K | 109.00K | 62.03K | 26.34K |
| Gross Profit | -150.00K | -167.00K | -109.00K | -62.03K | -26.34K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 53.54M | 40.69M | 26.91M | 17.63M | 11.37M |
| General & Administrative | 25.39M | 27.20M | 18.74M | 7.67M | 6.28M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 25.39M | 27.20M | 18.74M | 7.67M | 6.28M |
| Other Expenses | 0.00 | 342.00K | 96.00K | 241.00K | 24.00K |
| Operating Expenses | 78.93M | 67.88M | 45.65M | 25.30M | 17.64M |
| Cost & Expenses | 78.93M | 67.88M | 45.65M | 25.30M | 17.64M |
| Interest Income | 6.15M | 1.96M | 54.00K | 171.00K | 197.00K |
| Interest Expense | 0.00 | 0.00 | 10.00K | 49.00K | 39.00K |
| Depreciation & Amortization | 150.00K | 167.00K | 109.00K | 62.03K | 26.34K |
| EBITDA | -72.37M | -65.41M | -45.39M | -24.83M | -17.39M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -78.93M | -67.88M | -45.65M | -25.30M | -17.64M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 4.37M | 2.31M | 140.00K | 363.00K | 182.00K |
| Income Before Tax | -74.56M | -65.58M | -45.51M | -24.94M | -17.46M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -2.04M | 908.00K | 1.50M | -15.00K | 166.00K |
| Net Income | -74.56M | -66.49M | -47.01M | -24.93M | -17.63M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.84 | -2.09 | -1.46 | -0.78 | -0.55 |
| EPS Diluted | -1.84 | -2.09 | -1.46 | -0.78 | -0.55 |
| Weighted Avg Shares Out | 40.45M | 31.82M | 32.13M | 32.13M | 32.13M |
| Weighted Avg Shares Out (Dil) | 40.45M | 31.82M | 32.13M | 32.13M | 32.13M |
AbCellera and Rallybio Announce Strategic Alliance to Discover, Develop, and Commercialize Novel Antibody-Based Therapeutics for Rare Diseases
AbCellera and Rallybio Announce Strategic Alliance to Discover, Develop, and Commercialize Novel Antibody-Based Therapeutics for Rare Diseases
Rallybio to Present at the JMP Securities Hematology and Oncology Summit
Rallybio to Present at the JMP Securities Hematology and Oncology Summit
Rallybio to Present at Upcoming Investor Conferences in November
Rallybio to Present at Upcoming Investor Conferences in November
Rallybio Announces Pricing of $50 Million Public Offering
Rallybio Announces Proposed Public Offering
Rallybio Reports Third Quarter 2022 Financial Results
Rallybio Announces Positive Phase 1 Single Ascending Dose Results for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5
Source: https://incomestatements.info
Category: Stock Reports